PROTEIN-POLYSACCHARIDE PNEUMOCOCCAL CONJUGATE VACCINES

该提案是为了开发一种多价的 安全的肺炎球菌结合疫苗， 能有效对抗由链球菌引起的疾病 肺炎在成人和婴儿。 几种不同 将检查替代载体蛋白以优化 抗体对糖的反应，并增加 疫苗的成功研制。 疫苗将 含有七种已知会导致严重疾病的血清型 在这个国家和第三世界国家。 适当 将进行实验室测试以确定毒性， 致热原性、超敏反应和一般安全性 疫苗。 在动物中进行安全性测试后，疫苗将 在成人中进行安全性和免疫原性测试，然后 儿童和婴儿。 预计这种疫苗将 显著降低与下列疾病相关的发病率和死亡率： 侵袭性肺炎球菌感染，也有很大的影响， 与婴儿中耳炎相关的发病率和费用 人口

The proposal is for the development of a multivalent pneumococcal conjugate vaccine(s) which will be safe and effective in combating disease produced by Streptococcus pneumoniae in both adults and infants. Several different alternative carrier proteins will be examined to optimize the antibody response to the saccharide and enhance the likelihood for the successful development of this vaccine(s). The vaccine(s) will contain seven serotypes which are known to cause serious disease both in this country and third world countries. Appropriate laboratory tests will be performed to determine the toxicity, pyrogenicity, hypersensitivity and general safety of the vaccine(s). Following safety testing in animals, the vaccine(s) will be tested for safety and immunogenicity in adults, followed by children and infants. It is anticipated that such a vaccine will reduce significantly the morbidity and mortality associated with invasive pneumococcal infections and also have a great impact on the morbidity and costs associated with otitis media in the infant population.